An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00859313
Recruitment Status : Completed
First Posted : March 11, 2009
Results First Posted : February 27, 2012
Last Update Posted : March 1, 2012
Information provided by (Responsible Party):
AcelRx Pharmaceuticals, Inc.

March 9, 2009
March 11, 2009
January 25, 2012
February 27, 2012
March 1, 2012
April 2009
August 2009   (Final data collection date for primary outcome measure)
Percent of Patients Without Device Failure [ Time Frame: 12 hours ]
Percent of patients who completed the study without a device failure. A device failure is defined as the failure to dispense a NanoTab, dispensing more than one NanoTab, or dispensing a broken NanoTab. Device failures were monitored and reported by study staff.
To evaluate the functionality of the NanoTab™ Delivery System for patient self-administration of ARX-F01 NanoTabs™ to the sublingual cavity. [ Time Frame: 12-hrs post-dose ]
Complete list of historical versions of study NCT00859313 on Archive Site
Not Provided
To evaluate the safety, efficacy, and tolerability of the NanoTab™ Delivery System /ARX-F01. [ Time Frame: 12-hours post-dose ]
Not Provided
Not Provided
An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement
An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab® Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement

This study is being performed to evaluate the functionality of a device (Sufentanil NanoTab® PCA System) that has been developed for use by patients to self-administer the ARX-F01 pain medication (Sufentanil NanoTab 15 mcg) for the treatment of post-operative pain after undergoing knee replacement surgery.

Another goal of this study is to assess the safety and effectiveness of this non-invasive, sublingual route of administration of ARX-F01 in decreasing the amount of pain that a patient experiences following knee replacement surgery.

Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pain, Postoperative
Drug: Sufentanil NanoTab PCA System/15 mcg
15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Experimental: Sufentanil NanoTab PCA System/15 mcg
Intervention: Drug: Sufentanil NanoTab PCA System/15 mcg
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female patients between 45 and 80 years of age.
  2. Patient is scheduled for an elective unilateral, unicondylar, bi- or tri-compartmental, cemented or uncemented knee replacement under general or spinal anesthesia that does not include use of an intrathecal opioid.
  3. Patient must be classified as American Society of Anesthesiologists (ASA) class I - III.
  4. Patient must have a Body Mass Index (BMI) between 18 and 39, inclusively.
  5. Female patients of childbearing potential must be using an effective method of birth control from the screening visit through the end of study. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for ≥1 year, must be specified in the patient's CRF.
  6. The patient must be willing and able to understand the study procedures and the use of pain scales, and to communicate meaningfully with the study personnel.
  7. The patient must have the manual dexterity to handle the Sufentnail NanoTab PCA System and be able to follow directions for its use.
  8. The patient must provide written informed consent and sign the Informed Consent approved by the Institutional Review Board (IRB).

Exclusion Criteria:

  1. Patient has previously undergone a knee replacement of the same knee.
  2. A passive range-of-motion (PRM) will be used before the 12-hour study period is complete.
  3. Patient has previously not responded to opioid analgesics for treatment of pain.
  4. Patient is currently taking or has taken an opioid for more than 30 consecutive days of daily use at a daily dose equivalent of greater than 15 mg morphine within the past three months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
  5. Patient has an allergy or hypersensitivity to opioids.
  6. Patient is taking monoamine oxidase inhibitors (MAOIs), or has taken MAOIs within 14 days prior to enrolling in the study.
  7. Patient currently has sleep apnea that has been documented by a sleep laboratory study.
  8. Patient has any screening laboratory test value outside the laboratory normal range which is considered clinically significant by the Investigator.
  9. Patient is a woman who is pregnant or lactating.
  10. Patient has psychiatric disease or encephalopathy severe enough to prevent patient from providing reliable study documentation.
  11. Patient, in the Investigator's judgment, does not have adequate ability to read and understand English.
  12. Patient has a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including fracture or active infection.
  13. Patient has clinically significant renal or liver impairment which could affect metabolism or clearance of sufentanil.
  14. Patient has a painful physical condition other than knee arthritis that, in the opinion of the Investigator, may confound post-operative pain assessments.
  15. Patient has a history of drug, prescription medicine, or alcohol abuse within the past 2 years or a positive drug screen test for cocaine, amphetamines, barbiturates, phencyclidine, or methadone at screening.
  16. Patient is receiving oxygen therapy at the time of screening.
  17. Patient participated in a clinical trial of an investigational drug or device within 30 days of screening visit or is scheduled to receive an investigational product other than the Sufentanil NanoTab PCA System while participating in this study.

Exclusion Criteria Prior to Treatment Initiation:

  1. Patient has a respiratory rate that is less than 8 breaths per minute or greater than 24 breaths per minute.
  2. Patient has arterial oxygen saturation by pulse oximetry (SpO2) of less than 90% with supplemental oxygen.
  3. Patient is not able to answer questions and follow commands.
  4. Patient has vomiting that is not responsive to standard treatment.
  5. The surgical procedure from incision to closure lasted more than 3 hours.
  6. There have been any deviations from the surgical or anesthetic protocols as specified in Section
Sexes Eligible for Study: All
45 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
Not Provided
Study Director: Pamela P Palmer, MD PhD AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP